Get the Stockscreener App
8.52
0.12%
0.010
After Hours:
8.52
Y Mabs Therapeutics Inc stock is traded at $8.52, with a volume of 998.99K.
It is up +0.12% in the last 24 hours and up +95.41% over the past month.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
See More
Previous Close:
$8.51
Open:
$8.51
24h Volume:
998.99K
Relative Volume:
1.65
Market Cap:
$385.92M
Revenue:
$84.82M
Net Income/Loss:
$-21.43M
P/E Ratio:
-17.39
EPS:
-0.49
Net Cash Flow:
$-27.23M
1W Performance:
+103.34%
1M Performance:
+95.41%
6M Performance:
+47.66%
1Y Performance:
-24.00%
1-Day Range:
$8.51
$8.53
1-Week Range:
$8.495
$8.54
52-Week Range:
$3.55
$16.11
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
Name
Y Mabs Therapeutics Inc
Sector
Industry
Phone
646-885-8505
Address
202 CARNEGIE CENTER, PRINCETON, NY
Compare YMAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
YMAB
Y Mabs Therapeutics Inc
|
8.52 | 386.68M | 84.82M | -21.43M | -27.23M | -0.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.46 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.00 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.94 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
638.90 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
289.75 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-18-24 | Initiated | Oppenheimer | Outperform |
| Aug-16-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-28-24 | Initiated | Truist | Buy |
| May-10-23 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-27-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-05-23 | Downgrade | Cowen | Outperform → Market Perform |
| Dec-02-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-31-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-31-22 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-03-22 | Resumed | Guggenheim | Buy |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-16-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-07-21 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-23-21 | Resumed | Cowen | Outperform |
| Mar-22-21 | Resumed | JP Morgan | Overweight |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| May-05-20 | Initiated | Barclays | Overweight |
| May-01-20 | Initiated | Janney | Buy |
| Apr-29-20 | Initiated | Morgan Stanley | Equal-Weight |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Initiated | Wedbush | Outperform |
| Apr-01-19 | Initiated | H.C. Wainwright | Buy |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Oct-16-18 | Initiated | BofA/Merrill | Buy |
View All
Y Mabs Therapeutics Inc Stock (YMAB) Latest News
Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Rating Lowered by Truist Financial - MarketBeat
Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Rating Lowered by Brookline Capital Management - MarketBeat
DeFi Technologies Provides Monthly Corporate Update: Valour Reports US$947 Million (C$1.3 Billion) in AUM, and Monthly Net Inflows of US$14.4 Million (C$19.8 Million) in July 2025, Among Other Key Developments - The Globe and Mail
Y-mAbs Therapeutics (NASDAQ:YMAB) Given Hold Rating at Jones Trading - MarketBeat
Y-mAbs Therapeutics (NASDAQ:YMAB) Earns "Neutral" Rating from HC Wainwright - MarketBeat
Y-mAbs Therapeutics 2025 Q2 Earnings Narrowed Losses and Pending Acquisition - AInvest
Y-mAbs Therapeutics Reports Q2 Earnings and Acquisition - TipRanks
SERB Pharmaceuticals Acquires Y-MAbs As Revenue Slides - Finimize
Y-mAbs (YMAB) Q2 Revenue Falls 14% - AOL.com
Y-mAbs Therapeutics Q2 Earnings: Revenue Meets Expectations, EPS Below Consensus - AInvest
Y-mAbs Therapeutics Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView
Y mAbs Therapeutics earnings beat by $0.19, revenue topped estimates - Investing.com Canada
Y-mabs sold to Serb Pharmaceuticals for USD 412m - medwatch.com
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates - sharewise.com
Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public Shareholders - The Joplin Globe
Y-mAbs (YMAB) Q2 Revenue Falls 14% - The Motley Fool
Y-mAbs Therapeutics, Inc. SEC 10-Q Report - TradingView
Y-mAbs Therapeutics, Inc. Q2 2025 Financial Results - TradingView
Y-mAbs Q2 rev. $19.5mln, exceeds guidance, acquires Y-mAbs for $412mln. - AInvest
Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments - The Manila Times
Y-mAbs Acquisition: SERB Pays 105% Premium in $412M Deal While Q2 Revenue Exceeds Guidance - Stock Titan
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ARIS, YMAB, HLVX on Behalf of Shareholders - The Malaysian Reserve
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) - PR Newswire
A Look Ahead: Y-mAbs Therapeutics's Earnings Forecast - 富途牛牛
Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc.YMAB - Business Wire
Y-mAbs Q2 2025 Earnings Tomorrow: Key Updates Coming Amid SERB Pharma Transaction - Stock Titan
YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains? - MSN
Mayer Brown advises the group Serb Pharmaceuticals on the structuring of the take-private of Y-mAb Therapeutics Inc. - Mayer Brown
BSR REIT ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS - The Globe and Mail
YmAbs Therapeutics' 103.3% Surge: A Sustainable Bull Case or a Volatile Flash in the Pan? - AInvest
Y-mAbs Therapeutics Stock Surges 103.3% on Acquisition Deal with SERB Pharmaceuticals - AInvest
Y-mAbs Therapeutics: A Biotech M&A Deal that Highlights the Value and Challenges of the Industry - AInvest
Y-mAbs Therapeutics: The Next Deal Showcases The Value And Challenges Of Biotech M&A - Seeking Alpha
Oppenheimer Downgrades Y-mAbs Therapeutics to Market Perform From Outperform, Adjusts Price Target to $3 From $4 - MarketScreener
Canaccord Genuity Downgrades Y-mAbs Therapeutics to Hold From Buy, Adjusts Price Target to $8.60 From $26 - MarketScreener
SERB Pharma to acquire Y-mAbs Therapeutics for $412m - World Pharmaceutical Frontiers
Wedbush Downgrades Y-mAbs Therapeutics to Neutral From Outperform, Cuts Price Target to $8.60 From $18 - MarketScreener
Y-mAbs Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
SERB bets on rare cancer drug in $412 million deal for Y-mAbs - The Pharma Letter
YmAbs Therapeutics (YMAB) Upgraded to Buy: Here's What You Should Know - MSN
Y-mAbs stock soars over 100% after acquisition deal with SERB S.A.S. - Mugglehead Magazine
Y-mAbs Therapeutics downgraded to Hold from Buy at Canaccord - TipRanks
Y-mAbs Therapeutics stock downgraded to Hold by Truist after SERB acquisition - Investing.com Canada
Y-mAbs Therapeutics downgraded to Hold from Buy at Brookline - TipRanks
Hold Rating Issued Amidst SERB Pharmaceuticals’ Acquisition of Y-mAbs Therapeutics - TipRanks
Y-mAbs strategic review culminates in buyout by SERB Pharma - FirstWord Pharma
Specialty pharma SERB to buy Y-mAbs in $412M all-cash deal - Endpoints News
Top Midday Gainers - MarketScreener
Y-mAbs Therapeutics downgraded to Hold from Buy at Clear Street - TipRanks
Nasdaq Down 50 Points; ISM Services PMI Declines In JulyAmeresco (NYSE:AMRC), Agilon Health (NYSE:AGL) - Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Y Mabs Therapeutics Inc Stock (YMAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.02%
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):